The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma

Archives of Oral Biology

Volumn 46, Issue 6, 2001, Pages 487-493

  Nagler, Rafael M ^a   Gez, Eliyahu ^a   Rubinov, Rafael ^a   Laufer, Dov ^a   Ben Aryeh, Hanna ^a   Gaitini, Diana ^a   Filatov, Margarita ^a   Kuten, Abraham ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Composition; Function; Renal cell carcinoma; rIFN ; rIL 2; Saliva; Salivary glands

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CALCIUM; INTERLEUKIN 2; MAGNESIUM; PHOSPHATE; PROLEUKIN 2; PROTEIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; SALIVA PROTEIN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHEMICAL COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; MALE; METASTASIS; SALIVA; SALIVA ANALYSIS; SALIVARY GLAND; SALIVARY GLAND FUNCTION; SALIVATION; SECRETION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CALCIUM; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-2; MAGNESIUM; MALE; MIDDLE AGED; PHOSPHATES; RECOMBINANT PROTEINS; SALIVA; SALIVARY GLANDS; SALIVARY PROTEINS; SECRETORY RATE; STATISTICS; XEROSTOMIA;

EID: 0034999539     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9969(01)00008-5     Document Type: Article

References (35)

1. Baum J.B., Costa P.T., Izutsu T.K. Sodium handling by aging human parotid glands is inconsistent with a two-stage secretion model. Am. J. Phys. 246:1984;35-39.
2. Ben-Aryeh H., Serouya R., Kanter Y., Szargel R., Laufer D. Oral health and salivary composition in diabetic patients. J. Diabetes Complications. 7:1993;57-62.
3. Ben-Aryeh H., Jungerman T., Szargel R., Klein E., Laufer D. Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol. Psychiatry. 39:1996;946-949.
4. Blaise D., Viens P., Olive D., Stoppa A.M., Gabert J., Pourreau C.N., Attal M., Gaspard M.H., Mannoni P., Jasmin C. Recombinant interleukin-2 [rIL-2] after autologous bone marrow transplantation [BMT]: a pilot study in 19 patients. Eur. Cytokine Netw. 2:1991;121-129.
5. Boumba D., Skopouli F.N., Moutsopoulos H.M. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br. J. Rheumatol. 34:1995;222-326.
6. Coll J., Tomas S., Vilella R., Corominas J. Interleukin-2 receptor expression in salivary glands of patients with Sjogren's syndrome. J. Rheumatol. 22:1995;1488-1491.
7. Costello R., Blaise D., Jacquemier J., Monges G., Stoppa A.M., Viens P., Olive D., Bouabdallah M., Brandely M., Gastaut J.A. Induction of cutaneous graft-versus-host like reaction by recombinant IL-2 after autologous bone marrow transplantation. Bone Marrow Transplant. 16:1995;199-200.
8. Devi M.A., Das N.P. Antiproliferative effect of polyunsaturated fatty acids and interleukin-2 on normal and abnormal human lymphocytes. Experimentia. 50:1994;489-492.
9. Fox P.C., van der Ven P.F., Sonies B.C., Weiffenbach J.M., Baum B.J. Xerostomia: evaluation of a symptom with increasing significance. J. Am. Dent. Assoc. 110:1985;519-525.
10. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:1995;688-696.
11. Hanninen E.L., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 155:1996;19-25.
12. Hay D.I., Schlesinger D.H., Moreno E.C. Phosphoprotein inhibitors of calcium phosphate precipitation from human salivary secretions. Inorganic Perspectives of Biological Medicine. 2:1979;271-274.
13. Hofmockel G., Langer W., Theiss W.L., Gruss A., Frohmuller H.G. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J. Urol. 156:1996;18-21.
14. Katz J., Weiss H., Goldman B., Kanety H., Stannard B., LeRoith D., Shemer J. Cytokines and growth factors modulate cell growth and insulin-like growth factor binding protein secretion by the human salivary cell line [HSG]. J. Cell Physiol. 165:1995;223-227.
15. Klapholz L., Ackerstein A., Goldenhersh M.A., Vardy D., Nagler A. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2α immunotherapy following ABMT. Bone Marrow Transplant. 11:1993;443-446.
16. Konno H., Maruo Y., Matin A.F., Tanaka T., Nakamura S., Baba S., Yamashita A., Tadakuma T. Effect of liposomal interleukin-2 on ascites-forming rat hepatoma. J. Surg. Oncol. 51:1992;33-37.
17. Lowry O.H., Rosebrough N.J., Farr A.L., et al. J. Biol. Chem. 193:1951;265.
18. Mancini G., Carbonara A.D., Heremans J.F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 2:1965;235-254.
19. Mandel I.D. The role of saliva in maintaining oral homeostasis. J. Am. Dent. Assoc. 119:1989;298-304.
20. Marmary Y., Shiloni E., Katz J. Oral changes in interleukin-2 treated patients: a preliminary report. J. Oral Pathol. Med. 21:1992;230-231.
21. Marmary Y., Okon E., Katz J., Shiloni E. Effect of interleukin-2 on salivary gland morphology and function in mice. Lymphokine Cytokine Res. 13:1994;197-201.
22. Massumoto C., Benyunes M.C., Sale G., Beauchamp M., York A., Thompson J.A., Buckner C.D., Fefer A. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant. 17:1996;351-356.
23. Meehan K.R., Verma U.N., Rajogopal C., Cahill R., Frankel S., Mazunder A. Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. J. Infusional Chemotherapy. 6:1996;28-32.
24. Morecki S., Nagler A., Puyesky Y., Nabet C., Condiotti R., Pick M., Gan S., Slavin S. Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity. Lymphokine Cytokine Res. 12:1993;159-165.
25. Nagler R.M., Marmary Y., Krausz Y., Chisin R., Markitziu A., Nagler A. Major salivary gland dysfunction in human acute and chronic graft-versus-host disease. Bone Marrow Transplant. 17:1996;219-224.
26. Nagler R.M., Laufer D., Nagler A. Parotoid gland dysfunction in an animal model of chronic graft vs host disease. Arch. Otolaryngol. Head Neck Surg. 122:1996;1057-1060.
27. Nagler A., Ackerstein A., Or R., Naparstek E., Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients post-autologous marrow or stem cell transplantation. Blood. 89:1997;3951-3959.
28. Nagler A., Nagler R., Ackerstein A., Levi S., Marmary Y. Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation [ABSCT]. Bone Marrow Transplant. 20:1997;575-580.
29. Nagler R.M., Laufer D., Nagler A. Parotid gland dysfunction in a murine model of acute graft versus host disease. Head Neck. 10:1998;58-62.
30. Nagler R.M., Nagler A. Pilocarpine hydrochloride relieves xerostomia in chronic graft vs host disease patients: a sialometrical study. Bone Marrow Transplant. 23:1999;1007-1011.
31. Nedwin G.E., Svedersky L.P., Bringman T.S., Palladino M.A. Jr., Goeddel D.V. Effect of interleukin-2, interferon-gamma and mitogens on the production of tumor necrosis factors alpha and beta. J. Immunol. 135:1985;2492-2497.
32. Ohyama Y., Nakamura S., Matsuzaki G., Shinohara M., Hiroki A., Fujimura T., Yamada A., Itoh K., Nomoto K. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 39:1996;1376-1384.
33. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., Kopf M. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science. 264:1994;561-563.
34. Via C.S., Finelman F.D. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int. Immunol. 5:1993;565-572.
35. Walker N.I., Gobe G.C. Cell death and cell proliferation during atrophy of the rat parotid gland induced by duct obstruction. J. Pathol. 153:1987;333-344.